Controversies concerning the use of neoadjuvant systemic therapy for primary breast cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22278605.
- Also identified by DOI 10.1007/s00268-012-1424-4.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The major aim of neoadjuvant systemic therapy is to improve prognosis by individualizing treatment. The proven benefits of neoadjuvant systemic therapy include reducing tumor burden, higher breast-conserving surgery, and the possibility of in vivo monitoring of response to treatment. Other goals of neoadjuvant treatment are the detection of new prognostic and predictive biomarkers and the investigation of new drugs and imaging modalities. Although many prospective trials have answered important questions regarding neoadjuvant systemic therapy, several topics remain controversial.
Medical subject headings
- Breast Neoplasms
- Neoadjuvant Therapy